Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | GFER | P55789 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | RAD51 | Q06609 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | FAAH | O00519 | 7/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | KCNQ3 | O43525 | 2/20 | 0.48 |
| ▸ | KCNQ2 | O43526 | 2/20 | 0.48 |
| ▸ | AR | P10275 | 1/20 | 0.48 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.47 |
| ▸ | PORCN | Q9H237 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL896642 | 1.00 | ALDH1A1 (0.52) | ALDH1A1MAPTMEN1KMT2AKDM4E | |
| SCHEMBL27794530 | 0.87 | ALDH1A1 (0.54) | ALDH1A1MAPTMEN1KMT2AKDM4E | |
| SCHEMBL27785451 | 0.86 | CHEK1 (0.45) | ALDH1A1MAPTMEN1KMT2AKDM4E | |
| SCHEMBL590790 | 0.83 | MAPT (0.47) | ALDH1A1MAPTMEN1KMT2AGAA | |
| SCHEMBL24757755 | 0.83 | ALDH1A1 (0.51) | ALDH1A1MAPTMEN1KMT2AKDM4E | |
| SCHEMBL31129270 | 0.81 | AR (0.57) | ALDH1A1MAPTMEN1KMT2AKDM4E | |
| SCHEMBL31125084 | 0.81 | CHEK1 (0.59) | ALDH1A1MAPTCHEK1 | |
| SCHEMBL2589885 | 0.81 | CHEK1 (0.59) | ALDH1A1MAPTCHEK1 | |
| SCHEMBL896314 | 0.80 | KCNQ3 (0.64) | ALDH1A1MAPTMEN1KMT2AKDM4E | |
| SCHEMBL27857353 | 0.80 | KCNQ3 (0.52) | MAPTMEN1KMT2AKDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4334298-B1 | UREA DERIVATIVES WHICH CAN BE USED TO TREAT CANCER | SCORPION THERAPEUTICS INC (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20250250259-A1 | METHODS FOR TREATING CANCER | SCORPION THERAPEUTICS, INC. | 2025-08-07 | — | — | US | disclosed |
| US-12312341-B2 | Methods for treating cancer | SCORPION THERAPEUTICS, INC. (US) | 2025-05-27 | — | — | US | disclosed |
| US-20240400543-A1 | METHODS FOR TREATING CANCER | SCORPION THERAPEUTICS, INC. | 2024-12-05 | — | — | US | disclosed |
| US-20240300939-A1 | UREA DERIVATIVES WHICH CAN BE USED TO TREAT CANCER | SCORPION THERAPEUTICS, INC. | 2024-09-12 | — | — | US | disclosed |
| US-12084434-B2 | Methods for treating cancer | SCORPION THERAPEUTICS, INC. (US) | 2024-09-10 | — | — | US | disclosed |
| EP-4334298-A1 | UREA DERIVATIVES WHICH CAN BE USED TO TREAT CANCER | Scorpion Therapeutics, Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| US-20240076289-A1 | METHODS FOR TREATING CANCER | SCORPION THERAPEUTICS, INC. | 2024-03-07 | — | — | US | disclosed |
| US-11897871-B1 | Methods for treating cancer | SCORPION THERAPEUTICS, INC. (US) | 2024-02-13 | — | — | US | disclosed |
| WO-2022265993-A1 | UREA DERIVATIVES WHICH CAN BE USED TO TREAT CANCER | SCORPION THERAPEUTICS, INC. (US) | 2022-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240300939-A1 | UREA DERIVATIVES WHICH CAN BE USED TO TREAT CANCER | PIK3CA, PIK3CG, PIK3CD | ALDH1A1 1105/4885MAPT 1252/4885MEN1 2890/4885 |
| US-11897871-B1 | Methods for treating cancer | PIK3CA, PTEN, BRCA1 | ALDH1A1 1084/4885MAPT 2262/4885MEN1 2531/4885 |
| US-12312341-B2 | Methods for treating cancer | PIK3CA, PTEN, BRCA1 | ALDH1A1 1084/4885MAPT 2262/4885MEN1 2531/4885 |
| US-20240076289-A1 | METHODS FOR TREATING CANCER | PIK3CA, PTEN, BRCA1 | ALDH1A1 1084/4885MAPT 2262/4885MEN1 2531/4885 |
| US-20250250259-A1 | METHODS FOR TREATING CANCER | PIK3CA, PTEN, BRCA1 | ALDH1A1 1084/4885MAPT 2262/4885MEN1 2531/4885 |
| US-20240400543-A1 | METHODS FOR TREATING CANCER | PIK3CA, PTEN, BRCA1 | ALDH1A1 1084/4885MAPT 2262/4885MEN1 2531/4885 |
| US-12084434-B2 | Methods for treating cancer | PIK3CA, PTEN, BRCA1 | ALDH1A1 1084/4885MAPT 2262/4885MEN1 2531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.